Novartis' Pluvicto is expected to dominate the market for radioligand therapies for prostate cancer, with ...

TG Therapeutics shares made new 52-week highs this week, helped in part by new Briumvi data presentations at ECTRIMS. Find ...

Earlier switch to atezolizumab after run-in with vemurafenib plus cobimetinib showed promise in improving OS rates in BRAF ...

Emergency Response Africa (ERA), a leading healthcare technology company in partnership with the Ogun State government, has ...

It is playing catch-up with a rival Lp(a) targeting antisense drug from Novartis and development partner Akcea, called pelacarsen, which is already in a phase 3 trial called HORIZON with major ...

Novartis AG Registered Shares NOVN.SW 12.05% ...

About 483,464 Nigerians have said that job losses and unemployment have led to them withdrawing over N200 billion from ...

Most medicines used worldwide are off-patent products – generic or biosimilar versions of branded medicines offering the same quality, safety, and efficacy at a lower price. They are the ‘silent ...

The global supply chain for critical generic medicines faces increasing challenges. The skewed economics of the generic medicines market need to be corrected.

Women had a lower probability of receiving any disease-modifying treatment (DMT) and were even less likely to get ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...